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COLON
Association study of PHOX2B as a candidate gene for
Hirschsprung’s disease
M Garcia-Barceló, M H Sham, V C H Lui, B L S Chen, J Ott, P K H Tam
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Background: Hirschsprung’s disease (HSCR) is a congenital disorder characterised by an absence of
ganglion cells in the nerve plexuses of the lower digestive tract. Manifestation of the disease has been
linked to mutations in genes that encode the crucial signals for the development of the enteric nervous
system—the RET and EDNRB signalling pathways. The Phox2b gene is involved in neurogenesis and
regulates Ret expression in mice, in which disruption of the Phox2b results in a HSCR-like phenotype.
Aims: To investigate the contribution of PHOX2B to the HSCR phenotype.
Methods: Using polymerase chain reaction amplification and direct sequencing, we screened
PHOX2B coding regions and intron/exon boundaries for mutations and polymorphisms in 91 patients
with HSCR and 71 ethnically matched controls. Seventy five HSCR patients with no RET mutations were
independently considered. Haplotype and genotype frequencies were compared using the standard
case control statistic.
Results: Sequence analysis revealed three new polymorphisms: two novel single nucleotide polymor-
phisms (A→G1364; A→C2607) and a 15 base pair deletion (DEL2609). Statistically significant differences
were found for A→G1364. Genotypes comprising allele G were underrepresented in patients (19% v
36%; χ2=9.30; p=0.0095 and 22% v 36%; χ2=7.38; p=0.024 for patients with no RET mutations).
Pairwise linkage disequilibrium (LD) analysis revealed no LD between physically close polymorphisms
indicating a hot spot for recombination in exon 3.
Conclusion: The PHOX2B A→G1364 polymorphism is associated with HSCR. Whether it directly con-
tributes to disease susceptibility or represents a marker for a locus in LD with PHOX2B needs further
investigation. Our findings are in accordance with the involvement of PHOX2B in the signalling path-
ways governing the development of enteric neurones.
Hirschsprung’s disease (HSCR), regarded as a multigenicneurocristopathy, is a congenital disorder in whichthere is an absence of ganglion cells in the nerve plex-
uses of the lower digestive tract. The condition presents in the
neonatal period as failure to pass meconium, chronic severe
constipation, colonic distention, secondary electrolyte distur-
bances, and sometimes enterocolitis and bowel perforation.
The estimated population incidence is 1/5000 live births.1
Males are 3.5–4.0 times more likely to be affected than
females.2 3 HSCR may occur with other neurodevelopmental
disorders such as Waardenburg syndrome type 4 (WS4),4 and
it may also be associated with a variety of other anomalies,
including chromosomal abnormalities and syndromes with a
Mendelian pattern of inheritance. Approximately 20% of
HSCR cases are familial, with a sibling recurrence risk of 4%.
Aganglionosis is due to a disorder of the enteric nervous
system (ENS) in which ganglion cells fail to innervate the
lower gastrointestinal tract during embryonic development.
The extent of the aganglionic segment is variable, and is
reflected in the severity of the disease. The genetic signals
critical for neural crest migration and differentiation into
enteric ganglia include genes encoding neurotrophic factors
and their receptors. Substantial evidence has been presented
to show that HSCR has a complex genetic aetiology requiring
the interaction of several unlinked genes, and possibly
environmental factors, to produce the phenotype.5–11
It has been postulated that the degree of expression of the
receptor tyrosine kinase gene (RET) is critical for the HSCR
phenotype.7 However, RET mutations account for only 20–30%
of HSCR cases and lack genotype-phenotype correlation due
to low penetrance, indicating that genes other than RET are
implicated in the disease. This has led to the search for other
susceptibility and modifying genes that could lead to HSCR.
Interestingly, HSCR genes identified so far mainly code for
protein members of two important signalling pathways
involved in the development of enteric ganglia: RET and
endothelin receptor B (EDNBR) signalling pathways. Interac-
tion between these two signalling pathways could modify RET
expression11 and therefore HSCR phenotype.7 12 Nevertheless,
for almost every HSCR gene described, incomplete penetrance
and variable expression of the HSCR phenotype has also been
observed.13 14 Therefore, other genes implicated in RET expres-
sion and/or intestinal neurodevelopment should be considered
as candidate genes for HSCR.
The paired mesoderm homeobox 2b gene (PHOX2B)
encodes a transcription factor (homeodomain protein) which
is involved in the development of several noradrenergic
neurone populations. In mice,Phox2b expression starts as soon
as enteroblasts invade the foregut mesenchyme and is
maintained throughout the development into enteric neu-
rones. Homozygous disruption of the Phox2b gene results in
absence of enteric ganglia, a feature which is reminiscent of
HSCR. Furthermore, there is no Ret expression in Phox2b
mutant embryos. This indicates that regulation of Ret by
Phox2b could account for failure of the ENS to develop.15 16
The human PHOX2B gene has been cloned and
sequenced.17 Its coding region consists of 945 base pairs (bp)
allocated in three exons, yielding a homeodomain protein of
314 amino acid residues.18
The compelling evidence of the murine model has made the
human PHOX2B gene an attractive target for exploration as a
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potential human HSCR gene. HSCR results from mutations
and/or single nucleotide polymorphisms (SNPs) in several
genes acting either alone or in combination. Thus the
hypothesis underlying this study is that mutations or polymor-
phisms in the PHOX2B gene may be associated with the HSCR
phenotype by directly affecting expression of the PHOX2B gene
product, by being in linkage disequilibrium (LD) with unknown
causative mutations or polymorphisms, or by becoming patho-
genic in the presence of mutations and/or polymorphisms in
other genes. Our data contribute to the molecular dissection of
HSCR and enable an understanding of how genetic interactions
lead to the HSCR phenotype. To our knowledge, this is the first
association study between PHOX2B and HSCR.
MATERIAL AND METHODS
Patients and controls
A total of 91 ethnic Chinese patients, diagnosed with HSCR
between 1984 and 2001, were included in this study. Diagno-
sis was made at Queen Mary Hospital, Hong Kong SAR, and
was based on histological examination of either biopsy or sur-
gical resection material for absence of enteric plexuses. Five
patients (one with total colonic aganglionosis (TCA), two with
long segment aganglionosis, and two with short segment
aganglionosis) had affected relatives (two unrelated families
in total). Eighty six patients were affected with sporadic HSCR
with the following phenotypes: four individuals with TCA;
seven with long segment aganglionosis; and 75 with short
segment aganglionosis. Nine patients with sporadic HSCR
were also affected with the following associated anomalies:
five with Down’s syndrome (short segment); one with
Waardenburg syndrome (TCA); one with renal agenesis (short
segment); one with parathyroid adenoma (short segment);
and one with desmoid tumour (short segment). Seventy five
of 91 patients had no causative mutations in the RET gene
(unpublished data). To better evaluate the relevance of
PHOX2B in HSCR, these 75 patients were also independently
assessed. Association analysis was therefore performed on
HSCR patients regardless of their RET mutation status and on
the group of 75 patients with no RET mutations .
Normal controls (71 individuals) were unselected unrelated
ethnic Chinese subjects from Hong Kong without a diagnosis
of HSCR.
DNA was extracted from peripheral blood as previously
described.19 All patients and controls assented to molecular
analysis. The study was approved by the local ethics
committee.
Polymerase chain reaction and DNA sequencing
Polymerase chain reaction (PCR) was used to amplify the
three coding regions (including their 5′ and 3′ flanking
sequences) of PHOX2B. For exons 1 and 2, PCR was performed
in a 25 µl reaction volume containing 100 ng genomic DNA; a
mixture of all four nucleotides (final concentration 0.2 mM for
each nucleotide); 2.5 µl of 10× reaction buffer; 0.5 µM of each
appropriate primer; 1 mM MgCl2; and 1.25 U of AmpliTaq Gold
polymerase (Applied Biosystems, Foster City, California, USA).
Due to its high GC content, amplification of exon 3 was
performed using the GC-RICH PCR System (Roche Molecular
Biochemicals, USA). Exon 3 PCR was performed in a 25 µl
reaction volume containing 100 ng genomic DNA; a mixture of
all four nucleotides (final concentration 0.2 mM for each
nucleotide); 5 µl of 5× GC-RICH PCR reaction buffer; 2.5 µl of
5 M GC-RICH resolution solution; 0.5 µM of each appropriate
primer; and 1.25 U of a blend of Taq DNA Polymerase and Tgo
DNA Polymerase. Primers used to amplify the three coding
regions, including intron-exon boundaries, were derived from
the PHOX2B gene sequence available in GenBank (accession
No AB015671). The primers were as follow (size of amplified
DNA is in parentheses; forward primer is shown first in each
set): exon 1: GACCTCAGACAAGGCATCTCA and AATTAC-
CCCTCCCTGCAATC (586 bp); exon 2: CTGCCGTATGACCT-
GACCTT and ACAGCCACACCAAATCCAGT (442 bp); and
exon 3: ACCCTAACCGGTGCTTTTCT and ACAATAGCCTT-
GGGCCTACC (687 bp). The cycling conditions for the three
exons were 95°C for eight minutes followed by 35 cycles of
95°C for one minute, 62°C for one minute, and 72°C for 45 sec-
onds. A final 10 minute extension was included at the end of
the 35 cycles. Prior to sequencing, PCR products were column
purified (Life Technologies, UK) to remove reaction buffer and
unincorporated primers, and visualised by running 5 µl of
each sample on 2% agarose gels. PCR products were screened
for mutations by direct sequencing using a dye terminator
cycle sequencing kit (ABI PRISM Big Dye Terminator v 2.0
Cycle sequencing kit; Applied Biosystems) and an ABI 3100
automated sequencer (Applied Biosystems). For those sam-
ples in which DNA sequence variation had been observed, PCR
amplification from genomic DNA and sequencing using both
forward and reverse primers were repeated up to five times.
Statistical analysis
Allele and genotype frequencies for each polymorphism in the
control group and in unrelated patients were calculated. Allele
and genotype frequency comparisons between the control and
patient groups were performed using χ2 tests.χ2 tests were also
performed to determine whether each polymorphism was in
Hardy-Weinberg equilibrium within each group.
The level of association between genotypes involving two or
three polymorphic sites and HSCR disease was assessed using
both χ2 contingency tables and the estimating haplotype
frequencies (EH) program.20 EH is a linkage utility program to
test and estimate linkage disequilibrium between different
markers or between a disease locus and markers. The EH pro-
gram uses the method of gene counting, which provides
maximum likelihood estimates of the haplotype frequencies.
Haplotype frequencies are estimated considering allelic
association/linkage disequilibrium (H1) among markers and
without (H0). The EH program also provides log likelihood, χ2,
and the number of degrees of freedom under hypotheses H0
and H1. EH is only applicable to unrelated individuals. To test
whether haplotype frequencies were significantly different
between cases and controls, we performed three separate
analyses using the EH program: on case subjects alone, on
control subjects alone, and on the combination of case and
control subjects. The three log likelihoods obtained (lnLcase,
lnLcontrol, and lnLcombined) were used to calculate the relevant sta-
tistic test T=[ln(Lcase) + ln(Lcontrol) − ln(Lcombined)].
Twice this value gives an approximate χ2 distribution with a
number of degrees of freedom (df) equal to the number of
haplotypes estimated under the hypothesis that allelic associ-
ation is allowed. The EH program, which assumes Hardy-
Weinberg equilibrium, was also used to estimate LD between
polymorphisms.
RESULTS
Polymorphic sites
By direct sequencing of the entire coding region and portions
of 5′ and 3′ flanking regions, we found two new SNPs and one
deletion in the PHOX2B gene (fig 1). Nucleotide positions are
defined in relation to the first nucleotide of the start codon,
which is designated position +1.
The first polymorphism identified was an A→G transition
(referred as A→G1364) in intron 2, 100 bp away from the
intron/exon boundary. We investigated the possibility of
A→G1364 being part of PHOX2B intronic splice regulation sites.
The PHOX2B intron 2 sequence was screened for branch sites
(additional intronic splice signals), but sequence analysis did
not indicate such a possibility.
The second polymorphism identified was an A→C change
(referred as A→C2607) in codon 253 of the PHOX2B exon 3.
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A→C2607 is a silent transition that does not alter the amino acid
sequence (GCA→GCC).
The third sequence variant was a 15 bp deletion (referred as
DEL2609) in exon 3, starting from codon 254 and just 2 bp
downstream of the A→C2607 polymorphism (fig 1). This 15 bp
deletion occurs in one of the two polyalanine stretches in the
C terminus, resulting in the loss of five alanine residues
(codons 254–258). The polyalanine region in the normal
PHOX2B protein (codons 245–264) may form α-helical struc-
tures and serve as a flexible linker.21 The functional
consequence of this deletion of five alanine residues is unclear
at present. Interestingly, among the 71 normal individuals
studied, nine had this deletion in one of their PHOX2B alleles.
We ruled out the possibility of this observed deletion being an
experimental artefact. Specific PCR amplification enzymes
were used to resolve the high GC sequence content of exon 3
(see methods). In addition, those samples with the deletion
were reamplified and resequenced 5–10 times.
Finally, in every sample analysed, we found an A at both
positions 243 and 1418 of the PHOX2B gene (intron 2 and 3,
respectively) (fig 1). The Genbank accession numbers for
PHOX2B (AB015671 and AF117979) record T and G, respec-
tively. These may represent sequencing errors in the GenBank
entries. Alternatively, the Chinese population analysed in this
study may have had these SNPs.
In addition to the three polymorphisms described in this
study, there are three other PHOX2B SNPs recorded in
GenBank. Polymorphism ss3136952 is a A→C2118 transition at
position 2118 of the PHOX2B gene (intron 2); polymorphism
ss1551093 is a T→A4457 transversion at position 4457 (end of 3′
untranslated region); and polymorphisms ss1551094 is a
C→A4517 transversion at position 4517 (end of 3′ untranslated
region). These polymorphisms were not examined in our
study as they are outside the coding regions and splice sites.
Allelic variation between patients and controls
To determine the significance of these three novel polymor-
phisms in HSCR, we conducted a case control association
study to investigate whether they were directly related to the
HSCR phenotype. Differences in allele frequencies between
the patient and control groups were not statistically signifi-
cant for any of the polymorphisms (A→G1364 χ2=2.41; p=0.12;
A→C2607 χ2=1.62; p=0.20; DEL2609 χ2=1.06; p=0.3). Also, there
were no statistically significant differences when the 75
patients with no RET mutations were compared with controls.
Within each group, allele frequencies of both sexes were com-
pared and no statistically significant differences for any of the
identified polymorphisms were found.
Genotype frequency distribution in patients and controls
Comparison of the genotype frequencies of the three new
polymorphisms between patients and controls (table 1)
revealed statistically significant differences for A→G1364
(χ2=9.30; p=0.0095). An association was also found when 75
patients with no mutations in RET were compared (χ2=7.38;
p=0.024). For this particular polymorphism, genotypes
comprising G were underrepresented in both patient groups:
19% (91 patients) versus 36% (71 controls) and 22% (75
patients) versus 36% (71 controls). Within each group, no sta-
tistically significant differences in genotype frequencies for
any of the identified polymorphisms were found between the
Figure 1 Polymorphisms identified in the PHOX2B gene. The three
PHOX2B exons are represented by rectangles. Black boxes indicate
the homeodomain. Hatched boxes indicate polyalanine stretches
(from codon 162 to 169 and from codon 245 to 264). Downward
arrows show the relative location of the polymorphisms.
    
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Table 1 Genotype frequency distribution of the PHOX2B gene polymorphisms
Polymorphism
Patients
Controls (n=71)
HSCR +/−RET mutations
(n=91)*
HSCR −RET mutations
(n=75) †
A→G1364
AA 0.81 (n=73) 0.77 (n=56) 0.64 (n=46)
AG 0.16 (n=15) 0.19 (n=14) 0.36 (n=25)
GG 0.03 (n=3) 0.03 (n=3) 0.00 (n=0)
χ2=9.30*; p=0.0095*; χ2=7.38 † ; p=0.024 †
A→C2607
AA 0.90 (n=82) 0.88 (n=64) 0.83 (n=59)
AC 0.10 (n=9) 0.12 (n=9) 0.17 (n=12)
CC 0.00 (n=0) 0.00 (n=0) 0.00 (n=0)
χ2=1.74* ; p=0.23* ; χ2=0.71 † ; p=0.39 †
DEL2609
NN‡ 0.92 (n=79) 0.90 (n=66) 0.87 (n=62)
ND§ 0.08 (n=7) 0.10 (n=7) 0.13 (n=9)
DD 0.00 (n=0) 0.00 (n=0) 0.00 (n=0)
χ2=1.11* ; p=0.29* ; χ2=0.41 † ; p=0.52 †
*HSCR patients regardless of their RET mutation status.
†HSCR patients with no RET mutations.
‡N no deletion.
§D deletion.
Table 2 Estimated haplotype frequencies in patients
and controls determined by estimating haplotype
frequencies
Haplotypes
FrequenciesIntron 2 Exon 3
A→G1364 A→C2607 DEL2609
Patients
(n=91)
Controls
(n=71)
All subjects
(n=162)
A A ND 0.855 0.777 0.821
A A D 0.029 0.031 0.030
A C ND 0.000 0.015 0.007
A C D 0.000 0.000 0.000
G A ND 0.056 0.075 0.064
G A D 0.009 0.032 0.019
G C ND 0.049 0.069 0.058
G C D 0.000 0.000 0.000
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sexes. Within each group, each of the three polymorphic sites
was in Hardy-Weinberg equilibrium.
Haplotype frequencies and linkage disequilibrium
among the three polymorphic sites
We were also interested in assessing the level of association
between HSCR disease and the genotypes involving two or three
polymorphic sites. When we used contingency tables to
compare frequencies of haplotypes generated by the combina-
tion A→G1364 + A→C2607 with the combination A→G1364 + DEL2609,
statistically significant differences between patients and con-
trols were found for both haplotype combinations (χ2=12.41;
p=0.014 and χ2=9.71; p=0.04, respectively). Contributions to χ2
were dissected and demonstrated that the major contribution
was that of genotypes of the polymorphic site A→G1364. In con-
trast, no statistically significant difference in frequencies was
found for the combination A→C2607 + DEL2609 (χ2=3.26; p=0.19).
When haplotypes comprising the three polymorphisms de-
scribed in this study were analysed for differences in
frequencies between patients and controls, no association was
found (χ2=11; p=0.08, 6 df). Similar results were obtained for
the 75 patients with no RET mutations
Using the EH program we estimated the haplotype
frequencies of the three polymorphisms combined (table 2).
The two most common haplotype combinations for both cases
and controls were A-A-ND and G-A-ND (allele designations as
shown in table 1). When haplotype frequencies were
compared, none of the haplotype combinations showed statis-
tically significant differences between patients and controls
(table 3). Using this program, we also assessed differences in
frequencies of haplotype combinations comprising only two
polymorphic sites. No statistically significant differences were
found. Similar results were found for the group of 75 patients
with no RET mutations (data not shown). Overall, these find-
ings are in agreement with the data obtained when
contingency tables were used: the association found was
driven by A→G1364.
Significant evidence for LD was found among the three
polymorphisms for both patients and controls, either analysed
independently or combined. These findings were not surpris-
ing given the close physical proximity of the markers. We also
assessed LD between two polymorphisms (table 4). The
A→G1364 polymorphism was in LD with A→C2607 in both
patients and controls, either analysed independently or
combined. Surprisingly, no LD was found between A→G1364
and DEL2609, nor between A→C2607 and DEL2609 despite being
only 2 bp apart. Similar results were obtained for the group of
75 patients (data not shown). These data strongly suggest that
only the A→G1364 polymorphism is associated with HSCR dis-
ease and that the discrepancies in the analysis of haplotype
frequencies are due to incomplete LD.
DISCUSSION
In this study, we sequenced the entire coding region of the
PHOX2B gene as well as intron/exon boundaries of ethnically
matched patients and controls in searching for mutations or
polymorphisms that could contribute to the clinical manifes-
tation of HSCR disease. We identified two new SNPs (A→G1364,
A→C2607) and one deletion (DEL2609).
A→C2607 is a silent transition that does not alter the amino
acid sequence. This polymorphism was also present in the
control population with no significant allele or genotype
frequency differences. Interestingly, DEL2609 showed no associ-
ation with HSCR despite causing the loss of five alanine resi-
dues in the PHOX2B protein. In both patients and controls,
DEL2609 was always heterozygous. The functional consequences
of this deletion are unclear at the moment. In mice,
heterozygous disruption of the Phox2b homeodomain shows
no obvious phenotype, but homozygous mutants are embry-
onically lethal. In those individuals carrying DEL2609, any func-
tional consequence caused by the DEL2609 polymorphism may
be compensated by the normal allele.
For A→G1364, we found statistically significant differences in
genotype distribution when patients were compared with con-
trols, indicating an association of the A→G1364 polymorphism
with HSCR. The association found could be due to a direct con-
tribution of A→G1364 to the HSCR phenotype or that A→G1364 is
in LD with another susceptibility locus. Direct involvement of
A→G1364 in HSCR disease would be through alteration of intronic
sequences crucial for splicing and/or regulation of expression of
the PHOX2B gene. Based on our branch site sequence analysis, it
is unlikely that the A→G1364 polymorphism is involved in alter-
native splicing of PHOX2B transcripts. As cis acting regulatory
elements for the PHOX2B gene have not been defined, at present
it is still unclear whether the A→G1364 polymorphism could
directly affect PHOX2B gene expression. It is possible that either
the PHOX2B A→G1364 polymorphism or other mutations in
PHOX2B need to occur together or act in combination with other
mutations in the RET and/or EDNRB signalling pathway genes
to produce the HSCR phenotype.A combination of specific vari-
ations in multiple genes of these signalling pathways may con-
fer either protection or susceptibility to the disease and even
modify the phenotype. Coexistence of RET mutations with
mutations or polymorphisms in GDNF and EDNRB genes have
been described in patients with HSCR.13 14 The association found
when patients with no mutations in RET coding regions were
examined indicate that A→G1364—or a locus in LD—could
directly contribute to the HSCR phenotype. Nevertheless,
A→G1364 may act in combination with any of the many
polymorphisms of the RET gene which are present in both the
healthy population and affected individuals, or RET mutations
could be in non-coding regions. Mutation analyses of the
EDNRB, EDN3, and GDNF genes in the same group of patients
are now in progress to investigate coexisting mutations with
Table 3 Association testing based on the haplotype
frequencies of A→G1364, A→C2607, and DEL2609
Group n* ln(L) χ2 p†
Patients 91 −90.84 36.54 0.42
Controls 71 −97.86 21.99
All subjects 162 −192.24 56.49
*Number of individuals.
†The relevant test statistic is T= ln(L, cases) + ln(L, controls) − ln(L,
cases+controls together). Twice this value has an approximate χ2
distribution with a number of degrees of freedom (df) equal to the
number of haplotypes estimated. For the above data: (−90.84) +
(−97.86) − (−192.24) = 3.54; χ2=2×3.54 = 7.08 which on 7 df is
associated with an empirical significance level of p=0.42.
Table 4 Pairwise linkage disequilibrium
Pairwise comparison
Patients (n=91) Controls (n=71) All subjects (n=162)
χ2 p χ2 p χ2 p
A→G1364 v A→C2607 34.67 0.00 15.07 0.0017 47.60 0.0001
A→G1364 v DEL2609 0.12 0.90 1.86 0.15 1.96 0.58
A→C2607 v DEL2609 0.72 0.86 1.64 0.65 2.20 0.53
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PHOX2B polymorphism. Recently, Gabriel and colleagues22
described two loci—3p21 and 19q12—as RET dependent modi-
fiers segregating in families affected with short segment agan-
glionosis. The PHOX2B gene maps to the 4p12 region, which is
not a predicted modifier loci for RET in familial HSCR. The
patients reported here were mainly sporadic cases of HSCR for
whom mutations in RET accounted for only 15% of cases
whereas approximately 50% of familial HSCR cases were due to
RET mutations.23 Nevertheless, the phenotypic effect of the
tPHOX2B contribution could depend on the number, severity,
and co-occurrence of polymorphisms and/or mutations in RET.
Our study provides evidence of the possible contribution of
PHOX2B to HSCR acting either alone or in combination.
The underrepresentation of the A→G1364 polymorphism may
indicate that the transition A→G1364 is relatively recent in evo-
lutionary terms, as shown by the relatively low frequency of
the allele G in the population. If the minor allele G conferred a
protective effect, its frequency in the population would be ris-
ing to become the major allele.24 We found LD among the three
polymorphisms that spread over 1.2 kb, which was expected
given their physical proximity. Interestingly, the pairwise dis-
equilibrium test showed lack of LD between A→G1364 versus
DEL2609 and between A→C2607 versus DEL2609 which are only two
base pairs apart. This indicates that the DEL2609 polymorphism
is probably situated in a recombination hot spot. Detailed
sequence examination of exon 3 (from nucleotides 2290 to
2805) in which this polymorphism is located showed that
there is a high GC content and these are runs of CGG repeats
which could serve as foci for recombination. Recombination
across the hot spot would explain the results obtained in the
pairwise disequilibrium test and haplotype analysis. This
suggests that if there are other polymorphisms or mutations
in and around the PHOX2B gene which are also contributing to
HSCR, they should be located upstream of the A→G1364
polymorphism. These other possible susceptibility loci would
not be in LD with the polymorphism (DEL2609) found in the
recombination hot spot that defines the breakpoint of a LD
block.25 Therefore, the DEL2609 polymorphism should not be
used as a marker in further linkage based association tests.
As the marker by marker approach ignores the polygenic
nature of HSCR disease and does not consider possible inter-
actions among susceptibility genes, it would be interesting to
investigate sets of SNPs in the different susceptibility loci
described for HSCR. Therefore, it would be necessary to
assemble an extensive catalogue of SNPs in these candidate
genes and perform association studies considering all of the
candidate genes together. Dissection of the genetic aetiology of
HSCR disease will help us in understanding other polygenic
complex disorders and congenital malformations considered
multifactorial in origin.
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